{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:33:00Z","timestamp":1794360780446,"version":"4.9.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Hepatocellular carcinoma (HCC) is currently the first indication of liver transplantation (LT) in Europe and Asia-Pacific region and the third in the United States. HCC recurrence is the main complication affecting short- and medium-term outcomes after LT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>A total of 433 consecutive adult recipients transplanted for HCC between 2000 and 2017 (mean age: 57.8 \u00b1 8.5 y; 83.8% were males) with a mean follow-up of 74.6 \u00b1 58.6 months were included. Patients had to meet Milan criteria and, since 2014, alpha-fetoprotein score to be listed. Patients with HCC recurrence were classified into early (\u22642 y) and late recurrence (&gt;2 y) and were retrospectively reviewed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Patients who developed recurrence (75 patients, 17%) had more tumors outside Milan and University of California San Francisco criteria, high alpha-fetoprotein score, and microvascular invasion at pathology. Early recurrence developed in 46 patients (61.3%); the overall 5- and 10-year survival rates of these patients from time of LT were 6.7% and 0%, which were significantly lower than those with late recurrence 64.0% and 27.1%, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The median survival times from the diagnosis of HCC recurrence were 15 and 17 months, respectively, in the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Multivariable Cox regression analysis identified alcoholic cirrhosis as etiology of the underlying liver disease (hazard ratio [HR] = 3.074; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007), bilobar tumor at time of LT (HR = 2.001; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.037), and a tumor size (&gt;50 mm) in the explant (HR = 1.277; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.045) as independent predictors of early recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Improving the prediction of early HCC recurrence could optimize patient selection for LT, potential adjuvant therapy with new targeted drugs and hence, improve long-term survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003434","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:33Z","timestamp":1599264033000},"page":"1778-1790","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":33,"title":["Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome"],"prefix":"10.1097","volume":"105","author":[{"given":"Nada","family":"El-domiaty","sequence":"first","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."},{"name":"Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Saliba","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vibert","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Karam","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Sobesky","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Statistics Department, Faculty of Economics and Political Science, Cairo University, Cairo, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pittau","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Ciacio","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chady","family":"Salloum","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Amer","sequence":"additional","affiliation":[{"name":"Hepato-Biliary and Liver Transplant Department, International Medical Center, Cairo, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaa A.","family":"Saeed","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan A.","family":"Shawky","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sa Cunha","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rosmorduc","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cherqui","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Adam","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Paul Brousse, Centre H\u00e9pato-Biliaire, Inserm UMR-S 1193, Universit\u00e9 Paris-Saclay, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma.","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/lt.24742","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?","volume":"23","author":"Fernandez-Sevilla","year":"2017","journal-title":"Liver Transpl"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2019.11.017","article-title":"Advances in resection and transplantation for hepatocellular carcinoma.","volume":"72","author":"Vibert","year":"2020","journal-title":"J Hepatol"},{"key":"R5-20250604","first-page":"527","article-title":"Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases.","volume":"12","author":"Sotiropoulos","year":"2007","journal-title":"Eur J Med Res"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gut.2008.149062","article-title":"Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis.","volume":"57","author":"Silva","year":"2008","journal-title":"Gut"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-6143.2009.02750.x","article-title":"Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor.","volume":"10","author":"Vibert","year":"2010","journal-title":"Am J Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/j.1600-6143.2007.01965.x","article-title":"Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging.","volume":"7","author":"Yao","year":"2007","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/lt.21842","article-title":"Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.","volume":"15","author":"D\u2019Amico","year":"2009","journal-title":"Liver Transpl"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study.","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria.","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/lt.21281","article-title":"Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.","volume":"13","author":"Ito","year":"2007","journal-title":"Liver Transpl"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000106910","article-title":"Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.","volume":"25","author":"Sugawara","year":"2007","journal-title":"Dig Dis"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1007\/s00268-011-1146-z","article-title":"Late recurrence of hepatocellular carcinoma after liver transplantation.","volume":"35","author":"Chok","year":"2011","journal-title":"World J Surg"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"58","DOI":"10.20517\/2394-5079.2017.05","article-title":"Late recurrence of hepatocellular carcinoma after liver transplantation.","volume":"3","author":"Zhang","year":"2017","journal-title":"Hepatoma Res"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis.","volume":"10","author":"Roayaie","year":"2004","journal-title":"Liver Transpl"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","article-title":"Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics.","volume":"266","author":"Bodzin","year":"2017","journal-title":"Ann Surg"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review.","volume":"21","author":"de\u2019Angelis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/tgh.2016.03.18","article-title":"Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.","volume":"1","author":"Khorsandi","year":"2016","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2014.03.038","article-title":"Building the multidisciplinary team for management of patients with hepatocellular carcinoma.","volume":"13","author":"Naugler","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.3748\/wjg.v24.i45.5081","article-title":"Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm.","volume":"24","author":"Au","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/lt.25419","article-title":"Liver transplantation in France.","volume":"25","author":"Durand","year":"2019","journal-title":"Liver Transpl"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1477-2574.2010.00228.x","article-title":"Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.","volume":"13","author":"DuBay","year":"2011","journal-title":"HPB (Oxford)"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.3748\/wjg.v21.i37.10604","article-title":"Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas.","volume":"21","author":"Yamakado","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"e13703","DOI":"10.1111\/ctr.13703","article-title":"Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma.","volume":"33","author":"Hong","year":"2019","journal-title":"Clin Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00534-012-0528-4","article-title":"Factors predicting survival after post-transplant hepatocellular carcinoma recurrence.","volume":"20","author":"Toso","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejso.2009.10.001","article-title":"Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.","volume":"36","author":"Kornberg","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/lt.22047","article-title":"Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma.","volume":"16","author":"Shin","year":"2010","journal-title":"Liver Transpl"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma.","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","article-title":"Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.","volume":"69","author":"Chan","year":"2018","journal-title":"J Hepatol"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1245\/s10434-015-4516-1","article-title":"Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early\/early stage hepatocellular carcinoma after surgical resection.","volume":"22","author":"Chan","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O","article-title":"Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.","volume":"89","author":"Poon","year":"2000","journal-title":"Cancer"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jhep.2012.06.033","article-title":"Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West.","volume":"57","author":"Lai","year":"2012","journal-title":"J Hepatol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/lt.23706","article-title":"Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.","volume":"19","author":"Lai","year":"2013","journal-title":"Liver Transpl"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jamcollsurg.2014.12.025","article-title":"A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.","volume":"220","author":"Agopian","year":"2015","journal-title":"J Am Coll Surg"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium.","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/TP.0000000000001752","article-title":"Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time \u201csweet spot\u201d.","volume":"101","author":"Mehta","year":"2017","journal-title":"Transplantation"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","article-title":"Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.","volume":"66","author":"Notarpaolo","year":"2017","journal-title":"J Hepatol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/SLA.0000000000001966","article-title":"Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story.","volume":"265","author":"Halazun","year":"2017","journal-title":"Ann Surg"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease.","volume":"70","author":"Ganne-Carri\u00e9","year":"2019","journal-title":"J Hepatol"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/j.hpb.2018.06.295","article-title":"Prediction model for early intrahepatic recurrence after hepatectomy for patients with hepatocellular carcinoma: an implication for adjuvant treatment.","volume":"20","author":"Ng","year":"2018","journal-title":"HPB"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"136","DOI":"10.14701\/ahbps.2018.22.2.136","article-title":"Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: lessons from two cases.","volume":"22","author":"Alshahrani","year":"2018","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"659","DOI":"10.12659\/AOT.910598","article-title":"Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation.","volume":"23","author":"Alshahrani","year":"2018","journal-title":"Ann Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1600-6143.2011.03689.x","article-title":"Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence.","volume":"11","author":"Toso","year":"2011","journal-title":"Am J Transplant"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","article-title":"Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.","volume":"59","author":"Sposito","year":"2013","journal-title":"J Hepatol"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1002\/lt.22367","article-title":"What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?","volume":"17 Suppl 2","author":"Duvoux","year":"2011","journal-title":"Liver Transpl"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.28339","article-title":"Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.","volume":"63","author":"Ferrer-F\u00e0brega","year":"2016","journal-title":"Hepatology"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jhep.2019.07.014","article-title":"Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.","volume":"71","author":"Zhou","year":"2019","journal-title":"J Hepatol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:14:54Z","timestamp":1749064494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003434","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}